Clinical Outcomes In Advanced Cervical Cancer (Cc) And Endometrial Cancer (Ec) Patients (Pts) Treated In Phase I Trials Of Novel Molecularly Targeted Agents (Mtas).

5596 Background: The prognosis for advanced CC and EC pts is poor, with relapse to approved chemotherapies inevitable. In view of the high rate of putative driver mutations, novel MTAs in phase I trials may benefit such pts. Methods: Retrospective study of pt records of CC (01/03-12/14) and EC (11/98-12/14) pts allocated to Phase I trials including efficacy expansion phases of MTAs in the Drug Development Unit at the Royal Marsden. Results: 93 CC pts were allocated to 51 trials (186 events); allocation was based on mutational profiles whenever possible. 57 (61%) pts began ≥ 1 trials (134 events). 36 (39%) pts did not start; 22 (24%) due to rapid progressive disease (PD), 7 (7.5%) due to other therapy options and 7 (7.5%) due to other reasons. 14 (10%) RECIST responses were seen; chemotherapy/MTA combinations (1 complete response and 7 partial responses [PR]), anti-angiogenics (AA) (2 PR), PI3K/AKT inhibitors (i) (2 PR) and immunotherapy (2 PR) in molecularly selected CC pts. 20 (15%) pts had RECIST stable...